Myelodysplastic Syndromes
Conditions
Keywords
Keywords provided by Celgene:, myelodysplastic syndromes, MDS, azacitidine, oral azacitidine (CC-486), decitabine, intermediate-1, intermediate-2 and high risk myelodysplastic syndromes (MDS), proliferative chronic myelomonocytic leukemia (CMML), Chronic, iHMA (injectable hypomethylating agents), PD-L1
Brief summary
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason for removing the combination arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm was closed to enrollment. Extension: An Extension Phase (EP) has been added to allow subjects who are currently receiving oral azacitidine BID and who are demonstrating clinical benefit as assessed by the Investigator, to continue receiving oral azacitidine until the subject meets the criteria for study discontinuation.
Interventions
DRUGOral Azacitidine
Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
DRUGDurvalumab
Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
Sponsors
Celgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, ≥ 18 years of age at the time of signing the informed consent document 2. Documented diagnosis of MYELODYSPLASTIC SYNDROMES (MDS), classified according to FRENCH-AMERICAN BRITISH (FAB) classification criteria 3. Adequate course of treatment with an injectable hypomethylating agent (azacitidine for injection or decitabine) as the last therapeutic intervention for MDS prior to beginning screening for this study. Adequate is defined as: * having received at least 6 consecutive 4-week treatment cycles with azacitidine for injection, or * having received at least 4 consecutive 6-week treatment cycles with decitabine (3-day regimen) or at least 6 consecutive 4-week treatment cycles with decitabine (5-day regimen), or * having demonstrated inability to tolerate treatment with an injectable hypomethylating agent because of unacceptable drug-related toxicity after at least 3 months of attempted treatment: Three 28-day cycles of azacitidine for injection or decitabine 5-day regimen; two 42-day cycles of decitabine 3-day regimen. 4. Documented disease progression or stable disease as best response to treatment (or attempted treatment) with azacitidine for injection or decitabine. Those achieving an objective response to treatment regimen with an injectable hypomethylating agent (HMA) are excluded from participation in this study. Definitions of disease progression are modified from INTERNATIONAL WORKING GROUP (IWG) 2006 criteria and include: \- Pre-injectable hypomethylating agent baseline bone marrow myeloblasts: 1. Less than 5%: ≥ 100% increase to ≥ 8% blasts 2. ≥ 5%: ≥ 50% increase to ≥ 10% blasts Note: ≥ 30% blasts is considered acute myeloid leukemia (AML )per FAB classification. Subjects known to have ≥ 30% blasts are not eligible for inclusion in this study.recognizing eastern cooperative oncology group) limitations of blast cell quantification, Protocol will allow subjects with pre-enrollment bone marrow blast counts up to 33% on the screening bone marrow examination to be considered for inclusion. Assessment may be made according to local bone marrow examination to facilitate enrollment of eligible subjects into the treatment phase of the study. \- Any clinical worsening from pre-injectable hypomethylating agents (HMA) baseline condition, including: <!-- --> 1. sustained clinically-significant worsening (investigator's assessment) from baseline granulocyte, platelet, or hemoglobin values (≥ 2 values, separated by ≥ 2 weeks) - worsening granulocytes should be ≥ 50% decrease from pre-injectable HMA baseline value - worsening platelets should be ≥ 50% decrease from pre-injectable HMA baseline value (untransfused) * worsening hemoglobin should be ≥ 1.5 g/dL decrease from preinjectable HMA baseline value in subjects not receiving RBC transfusions 2. meaningful worsening in RBC or platelet transfusion requirement Definition of stable disease is based on modified IWG 2006 criteria: * Failure to achieve any objective response (CR - complete remission, PR - partial remissino, mCR - marrow complete remission, or HI - hematologic improvement), but no evidence of disease progression within the 8 weeks leading to the subject's first dose of investigational product (IP), Cycle 1, Day 1 5. Have the last dose of the prior treatment regimen injectable HMA - (azacitidine for injection or decitabine) not more than 16 weeks prior to screening for this study (date of informed consent signature). 6. No less than 3 weeks between the last dose of the prior treatment regimen injectable HMA - (azacitidine for injection or decitabine) and the planned date of first dose of IP ( 7. Have an eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2 8. Females subjects of childbearing potential (FCBP)1 may participate, providing they meet the following conditions: 1. Have two negative pregnancy tests as verified by the investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence2 from heterosexual contact. 2. Agree to practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from 28 days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to 90 days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physician 3. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP. Note that the screening serum pregnancy test can also be used as the test prior to starting IP if it is performed within the 72-hour timeframe. 9\. Male subjects must: 1. Male subjects must: 1. Either practice true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of child bearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of azacitidine. 2. Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP. 10\. Understand and voluntarily sign an informed consent document prior to any study-related assessments or procedures conducted. 11\. Be able to adhere to the study visit schedule and other protocol requirements. 12\. Understand and voluntarily sign a biomarker-specific component of the informed consent document prior to any study-related procedures conducted. Extension Phase At the Investigator's discretion and following confirmation of eligibility criteria below, subjects can enter the Extension Phase (EP): * Subjects who have signed the informed consent for the EP of the study; * Subjects receiving oral azacitidine and continuing in the treatment phase demonstrating clinical benefit as assessed by the Investigator are eligible to receive oral azacitidine in the EP; * Subjects who do not meet any of the criteria for study discontinuation
Exclusion criteria
1. Rapidly-progressing MDS defined as: 1. Known clinically-significant doubling in marrow or per IP peripheral blood blast percentage (to ≥ 20%) in the 8-week period leading to the first dose of IP (Cycle 1, Day 1) 2. ≥100% increase in WBC count (myeloid cell line and monocyte series) within the 8-week period leading to Cycle 1, Day 1 2. AML - FAB (FRENCH-AMERICAN-BRITISH) classification: ≥ 30% blasts in bone marrow). Subjects known to have ≥ 30% blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to 33% to be considered for inclusion. 3. Prior allogeneic stem cell transplant 4. Prior exposure to the investigational oral formulation of decitabine, or other oral azacitidine derivative at any time in the subject's prior history 5. Prior or ongoing response (IWG 2006: HI, PR, CR, or marrow CR) to treatment with azacitidine for injection or decitabine, at any time in the subject's prior history, which includes relapsed disease 6. Ongoing medically significant adverse events from previous treatment, regardless of the time period 7. Use of any of the following within 28 days prior to the first dose of IP: 1. thrombopoiesis-stimulating agents (\[TSAs\]; eg, Romiplostim, Eltrombopag, Interleukin-11) 2. ESAs (Erythropoiesis stimulating agent) and other RBC hematopoietic growth factors (eg, interleukin-3) 3. hydroxyurea 8. Concurrent use of corticosteroids unless the subject is on a stable or decreasing dose for ≥ 1 week prior to enrollment for medical conditions other than MDS 9. History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the IP and/or predispose the subject to an increased risk of gastrointestinal toxicity 10. Prior history of malignancies, other than MDS, unless the subject has been free of the disease for ≥ 3 years. However, subjects with the following history/concurrent conditions are allowed: 1. Basal or squamous cell carcinoma of the skin 2. Carcinoma in situ of the cervix 3. Carcinoma in situ of the breast 4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system) 11. Significant active cardiac disease within the previous 6 months, including: 1. New York Heart Association (NYHA) class IV congestive heart failure; 2. Unstable angina or angina requiring surgical or medical intervention; and/or 3. Myocardial infarction 12. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment) 13. Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection 14. Any of the following laboratory abnormalities: 1. Serum Aspartate transaminase / Serum glutamic oxaloacetic transaminase (AST/SGOT) Alanine aminotransaminase / Serum glutamic pyruvate transaminase (ALT/SGPT) \> 2.5 x ULN (upper limit of normal) 2. Serum total bilirubin \> 1.5 x upper limit of normal (ULN). Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis). Subjects are excluded if there is evidence of autoimmune hemolytic anemia manifested as a corrected reticulocyte count of \> 2% with either a positive Coombs' test or over 50% of indirect bilirubin 3. Serum creatinine \> 2.5 x ULN (upper limit of normal) 4. Absolute WBC (white blood cell) count ≥ 20 x 109/L 15. Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody 16. Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females 17. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 18. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 19. Any condition that confounds the ability to interpret data from the study, including known or suspected conditions other than MDS, associated with anemia 20. Having received any prior MAb (monoclonal antibodies) against CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1, or PD-L1 or having received other investigational monoclonalantibodies (MAbs) within 6 months 21. Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemia 22. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[eg, colitis, Crohn's disease\], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome \[granulomatosis with polyangiitis\]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: 1. Subjects with vitiligo or alopecia; 2. Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ≥ 3 months; or 3. Subjects with psoriasis not requiring systemic treatment 23. History of primary immunodeficiency 24. Active myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukemia (CMML)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | The overall response rate (ORR) was defined as the percentage of participants who achieved an objective response including: hematologic improvement (HI), partial remission (PR), complete remission (CR), or marrow complete remission (mCR). Hematologic response was defined as: • CR: ≤ 5% myeloblasts with normal maturation of all cell lines; peripheral blood (PB) shows: hemoglobin ≥11 g/dL, neutrophils ≥1.0x10\^9/L, platelets ≥100x10\^9/dL, blasts (0%) • PR: same as CR bone marrow (BM) shows blasts decreased by ≥ 50% over pre-treatment but still \> 5%; cellularity and morphology not relevant • mCR: BM: ≤ 5% myeloblasts and decrease by ≥ 50% over pre-treatment PB, PB: if HI responses, noted in addition to mCR • HI: HI erythroid response (HI-E); HI neutrophil response (HI-N) ; HI platelet response (HI-P) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan Meier Estimate of Time to Onset of First and Best Response | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | Time to onset of first response was defined as the time between the date of first investigational product (IP) dose and the earliest date any response (CR, PR, mCR, or HI) was first observed. Participants who did not achieve any defined response during the treatment period were censored at the date of treatment discontinuation, disease progression, or death, whichever occurred first. Best response is the best recorded response or treatment outcome from the start of the study treatment until the end of the study treatment taking into account the requirements for confirmation of response. |
| Kaplan Meier Estimate of Duration of First Response | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first. |
| Kaplan Meier Estimate of Duration of Best Response | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first. |
| Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment. |
| Kaplan-Meier Estimate of Progression Free Survival (PFS) | From first dose to the first documented progressive disease (PD), relapse, or death due to any cause (Up to 91 months) | Progression-free survival is defined as the time from first dose to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to IWG 2006 response criteria for MDS. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence |
| Kaplan-Meier Estimate of Onset to Achieve Stable Disease | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment. |
| Kaplan-Meier Estimate of Duration of Stable Disease | Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms | The duration of stable disease was defined as the time between any two observations of objective disease progression (modified IWG criteria), starting from the first day of dosing with IP. Participants who maintained stable disease through the end of the treatment period were censored at the date of study termination. |
| Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML) | From first dose and until death, loss to follow-up, withdrawal of consent for further data collection (Up to 91 months) | For all participants who received at least one dose of study drug, continuous monitoring for progression to AML occurred in the post treatment follow up period. |
| Kaplan-Meier Estimate of Overall Survival | From first dose till death due to any cause (Up to 91 months) | Overall survival (OS) was defined as the time from randomization to death from any cause, and was calculated using date of first dose and date of death, or date of last follow-up for censored subjects. |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose until 28 days after the last dose of CC-486 (90 days after the last dose of durvalumab) or the last follow up visit, whichever date is later (Up to 91 months) | TEAEs were defined as AEs occurring or worsening on or after the date of the first dose of oral aza or durva and within 28 days after last dose of oral aza or 90 days after last dose of durva A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. |
| Serum Plasma Concentration of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Maximum Observed Concentration (Cmax) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Area Under Curve (AUC) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Time to Maximum Concentration (Tmax) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Terminal Half-life ( ½) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Clearance (CL/F) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Volume of Distribution (Vz/F) of Azacitidine and Durvalumab | Day 1, 8, 15 and 22 | Data was not collected |
| Kaplan-Meier Estimate of Time to Progression to AML | From first dose and until death, loss to follow-up, withdrawal of consent for further data collection (Up to 91 months) | Time to AML progression was defined as the time from the date of first dose of IP until the date the participant had documented progression to AML. |
Countries
Australia, Belgium, Canada, France, Germany, Italy, Poland, Spain, United Kingdom, United States
Participant flow
Recruitment details
Participants were randomized at 33 sites globally. The sites were located in: Australia (3), Europe (18) and the United States (12).
Pre-assignment details
Participants were eligible who did not respond to an adequate course of therapy with an injectable hypomethylating agent (iHMA - azacitidine or decitabine) or were unable to tolerate an iHMA following at least 3 months of attempted treatment.
Participants by arm
| Arm | Count |
|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred. | 32 |
| Progressive Disease (PD) Cohort: Oral Azacitidine Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred. | 22 |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred. | 6 |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred. | 5 |
| Total | 65 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 0 | 0 |
| Overall Study | Death | 21 | 18 | 3 | 5 |
| Overall Study | Site Closure by Sponsor | 5 | 1 | 2 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | Progressive Disease (PD) Cohort: Oral Azacitidine | Stable Disease Cohort: Oral Azacitidine and Durvalumab | Stable Disease (SD) Cohort: Oral Azacitidine | Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Total |
|---|---|---|---|---|---|
| Age, Continuous | 75.1 Years STANDARD_DEVIATION 7.56 | 70.0 Years STANDARD_DEVIATION 7.21 | 73.9 Years STANDARD_DEVIATION 7.62 | 72.4 Years STANDARD_DEVIATION 5.55 | 73.9 Years STANDARD_DEVIATION 7.42 |
| Average Red Blood Cell (RBC) Transfusion Requirement | 3.50 units per 56 days | 3.00 units per 56 days | 4.00 units per 56 days | 4.00 units per 56 days | 4.00 units per 56 days |
| Baseline Platelet Transfusion Status Dependent | 5 Participants | 0 Participants | 4 Participants | 1 Participants | 10 Participants |
| Baseline Platelet Transfusion Status Independent | 13 Participants | 6 Participants | 25 Participants | 4 Participants | 48 Participants |
| Baseline Platelet Transfusion Status Other | 4 Participants | 0 Participants | 3 Participants | 0 Participants | 7 Participants |
| Baseline Red Blood Cell (RBC) Transfusion Status Dependent | 7 Participants | 0 Participants | 8 Participants | 2 Participants | 17 Participants |
| Baseline Red Blood Cell (RBC) Transfusion Status Independent | 6 Participants | 3 Participants | 8 Participants | 2 Participants | 19 Participants |
| Baseline Red Blood Cell (RBC) Transfusion Status Other | 9 Participants | 3 Participants | 16 Participants | 1 Participants | 29 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 (Fully active) | 6 Participants | 3 Participants | 5 Participants | 2 Participants | 16 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 1 (Restricted but Ambulatory) | 13 Participants | 3 Participants | 22 Participants | 3 Participants | 41 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 2 (Ambulatory But Unable to Work) | 3 Participants | 0 Participants | 5 Participants | 0 Participants | 8 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 3 (Limited Self-Care) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 4 (Completely Disabled) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 5 (Death) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| French-American-British (FAB) Classification Chronic Myelomonocytic Leukemia (CMML) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| French-American-British (FAB) Classification Missing | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| French-American-British (FAB) Classification RAEB in Transformation | 3 Participants | 0 Participants | 2 Participants | 1 Participants | 6 Participants |
| French-American-British (FAB) Classification Refractory Anemia (RA) | 2 Participants | 0 Participants | 6 Participants | 0 Participants | 8 Participants |
| French-American-British (FAB) Classification Refractory Anemia with Excess Blasts (RAEB) | 16 Participants | 5 Participants | 17 Participants | 4 Participants | 42 Participants |
| French-American-British (FAB) Classification Refractory Anemia with Ringed Sideroblasts (RARS) | 1 Participants | 1 Participants | 6 Participants | 0 Participants | 8 Participants |
| International Prognostic Scoring System Risk Classification High (2) (≥ 2.5) | 8 Participants | 1 Participants | 8 Participants | 1 Participants | 18 Participants |
| International Prognostic Scoring System Risk Classification Intermediate 1 (0.5-1.0) | 5 Participants | 1 Participants | 12 Participants | 2 Participants | 20 Participants |
| International Prognostic Scoring System Risk Classification Intermediate (2) (1.0-2.0) | 7 Participants | 4 Participants | 7 Participants | 2 Participants | 20 Participants |
| International Prognostic Scoring System Risk Classification Low (0) | 2 Participants | 0 Participants | 4 Participants | 0 Participants | 6 Participants |
| International Prognostic Scoring System Risk Classification Unknown | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 MDS Associated with Isolated del (5q) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 MDS Unclassified (MDS-U) | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 4 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 Missing | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 RA With Excess Blasts-1 (RAEB-1) | 6 Participants | 1 Participants | 10 Participants | 2 Participants | 19 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 RA With Excess Blasts-2 (RAEB-2) | 11 Participants | 4 Participants | 8 Participants | 3 Participants | 26 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 Refractory Anemia (RA) with Ringed Sideroblasts | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Myelodysplastic Syndrome (MDS) World Health Organization Classification 2008 Refractory Cytopenia with Multilineage Dysplasia | 2 Participants | 1 Participants | 11 Participants | 0 Participants | 14 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Black | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Not Collected or Reported | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 21 Participants | 6 Participants | 30 Participants | 3 Participants | 60 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Unknown | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 18 Participants | 6 Participants | 28 Participants | 5 Participants | 57 Participants |
| Sex: Female, Male Female | 7 Participants | 0 Participants | 12 Participants | 0 Participants | 19 Participants |
| Sex: Female, Male Male | 15 Participants | 6 Participants | 20 Participants | 5 Participants | 46 Participants |
| Time Since Initial Diagnosis of MDS | 26.97 months STANDARD_DEVIATION 33.835 | 40.20 months STANDARD_DEVIATION 61.663 | 26.79 months STANDARD_DEVIATION 29.678 | 23.51 months STANDARD_DEVIATION 30.524 | 27.84 months STANDARD_DEVIATION 34.266 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 22 / 32 | 18 / 22 | 3 / 6 | 5 / 5 |
| other Total, other adverse events | 32 / 32 | 22 / 22 | 6 / 6 | 5 / 5 |
| serious Total, serious adverse events | 25 / 32 | 15 / 22 | 4 / 6 | 5 / 5 |
Outcome results
Primary
Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS)
The overall response rate (ORR) was defined as the percentage of participants who achieved an objective response including: hematologic improvement (HI), partial remission (PR), complete remission (CR), or marrow complete remission (mCR). Hematologic response was defined as: • CR: ≤ 5% myeloblasts with normal maturation of all cell lines; peripheral blood (PB) shows: hemoglobin ≥11 g/dL, neutrophils ≥1.0x10\^9/L, platelets ≥100x10\^9/dL, blasts (0%) • PR: same as CR bone marrow (BM) shows blasts decreased by ≥ 50% over pre-treatment but still \> 5%; cellularity and morphology not relevant • mCR: BM: ≤ 5% myeloblasts and decrease by ≥ 50% over pre-treatment PB, PB: if HI responses, noted in addition to mCR • HI: HI erythroid response (HI-E); HI neutrophil response (HI-N) ; HI platelet response (HI-P)
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: The intent-to-treat (ITT) population included all enrolled participants who received at least one dose of investigational product (IP).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) | 6.3 Percentage of Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) | 4.5 Percentage of Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) | 16.7 Percentage of Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) | 0 Percentage of Participants |
Secondary
Area Under Curve (AUC) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Clearance (CL/F) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Kaplan Meier Estimate of Duration of Best Response
Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: The ITT population included all enrolled participants who received at least one dose of IP; participants who achieved a best response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Duration of Best Response | NA Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Duration of Best Response | NA Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Duration of Best Response | NA Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Duration of Best Response | NA Months |
Secondary
Kaplan Meier Estimate of Duration of First Response
Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: The ITT population included all enrolled participants who received at least one dose of IP; participants who achieved a response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Duration of First Response | NA Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Duration of First Response | NA Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Duration of First Response | NA Months |
Secondary
Kaplan-Meier Estimate of Duration of Stable Disease
The duration of stable disease was defined as the time between any two observations of objective disease progression (modified IWG criteria), starting from the first day of dosing with IP. Participants who maintained stable disease through the end of the treatment period were censored at the date of study termination.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: The population includes participants who achieved stable disease as their best response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Duration of Stable Disease | NA Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Duration of Stable Disease | NA Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Duration of Stable Disease | NA Months |
Secondary
Kaplan-Meier Estimate of Onset to Achieve Stable Disease
A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: Includes all participants in the ITT population with progressive disease at baseline and achieved stable disease; those who didn't achieve SD or better were censored.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Onset to Achieve Stable Disease | NA Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Onset to Achieve Stable Disease | NA Months |
Secondary
Kaplan-Meier Estimate of Overall Survival
Overall survival (OS) was defined as the time from randomization to death from any cause, and was calculated using date of first dose and date of death, or date of last follow-up for censored subjects.
Time frame: From first dose till death due to any cause (Up to 91 months)
Population: The ITT population included all enrolled participants who received at least one dose of IP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Overall Survival | 17.00 Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Overall Survival | 6.28 Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Overall Survival | 14.70 Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Overall Survival | 14.56 Months |
Secondary
Kaplan-Meier Estimate of Progression Free Survival (PFS)
Progression-free survival is defined as the time from first dose to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to IWG 2006 response criteria for MDS. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence
Time frame: From first dose to the first documented progressive disease (PD), relapse, or death due to any cause (Up to 91 months)
Population: The ITT population included all enrolled participants who received at least one dose of IP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Progression Free Survival (PFS) | 14.86 Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Progression Free Survival (PFS) | 6.28 Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Progression Free Survival (PFS) | 14.70 Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Progression Free Survival (PFS) | 12.10 Months |
Secondary
Kaplan Meier Estimate of Time to Onset of First and Best Response
Time to onset of first response was defined as the time between the date of first investigational product (IP) dose and the earliest date any response (CR, PR, mCR, or HI) was first observed. Participants who did not achieve any defined response during the treatment period were censored at the date of treatment discontinuation, disease progression, or death, whichever occurred first. Best response is the best recorded response or treatment outcome from the start of the study treatment until the end of the study treatment taking into account the requirements for confirmation of response.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: The ITT population included all enrolled participants who received at least one dose of IP.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of First Response | NA Months |
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of Best Response | 3.68 Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of Best Response | 4.41 Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of First Response | 11.97 Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of First Response | NA Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of Best Response | 3.29 Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of First Response | NA Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan Meier Estimate of Time to Onset of First and Best Response | Onset of Best Response | 2.17 Months |
Secondary
Kaplan-Meier Estimate of Time to Progression to AML
Time to AML progression was defined as the time from the date of first dose of IP until the date the participant had documented progression to AML.
Time frame: From first dose and until death, loss to follow-up, withdrawal of consent for further data collection (Up to 91 months)
Population: The ITT population included all enrolled participants who received at least one dose of investigational product (IP).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Time to Progression to AML | NA Months |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Kaplan-Meier Estimate of Time to Progression to AML | NA Months |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Time to Progression to AML | 21.47 Months |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Kaplan-Meier Estimate of Time to Progression to AML | 6.21 Months |
Secondary
Maximum Observed Concentration (Cmax) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs were defined as AEs occurring or worsening on or after the date of the first dose of oral aza or durva and within 28 days after last dose of oral aza or 90 days after last dose of durva A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.
Time frame: From first dose until 28 days after the last dose of CC-486 (90 days after the last dose of durvalumab) or the last follow up visit, whichever date is later (Up to 91 months)
Population: The safety population included all enrolled participants who received at least 1 dose of IP and had at least 1 post-dose safety assessment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE | 32 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA or Durva | 4 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC Grade (GR) 3 or 4 TEAE | 32 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Oral AZA | 18 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T AZA or Durva | 18 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Oral AZA | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Dose Reduction of AZA | 10 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of AZA or Durva | 10 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of AZA or Durva | 15 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Related to (R/T) Oral Azacitidine (AZA) | 28 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Durvalumab (Durva) | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Oral AZA or Durva | 28 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE | 25 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA | 4 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death | 4 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T AZA or Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA | 21 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of Durva | 0 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA or Durva | 21 Participants |
| Stable Disease (SD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Discontinuation (D/C) of AZA | 15 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Durvalumab (Durva) | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Oral AZA | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Related to (R/T) Oral Azacitidine (AZA) | 20 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Dose Reduction of AZA | 8 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Oral AZA or Durva | 20 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE | 22 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA or Durva | 13 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA | 3 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T AZA or Durva | 10 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Discontinuation (D/C) of AZA | 8 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA | 13 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death | 4 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of AZA or Durva | 8 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Oral AZA | 10 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T AZA or Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC Grade (GR) 3 or 4 TEAE | 19 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Durva | 0 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA or Durva | 3 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE | 15 Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of AZA or Durva | 8 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC Grade (GR) 3 or 4 TEAE | 5 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T AZA or Durva | 4 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death | 2 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Oral AZA | 0 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T AZA or Durva | 0 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of Durva | 3 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of Durva | 0 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of AZA or Durva | 1 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of Durva | 2 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA | 3 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Durvalumab (Durva) | 5 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of AZA or Durva | 4 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE | 4 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA or Durva | 3 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA | 2 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Durva | 1 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA or Durva | 2 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Durva | 0 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE | 6 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Related to (R/T) Oral Azacitidine (AZA) | 6 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Oral AZA or Durva | 6 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Discontinuation (D/C) of AZA | 4 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Oral AZA | 4 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Dose Reduction of AZA | 1 Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Durva | 2 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Dose Reduction of AZA | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Oral AZA or Durva | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Durva | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE | 5 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE R/T Durvalumab (Durva) | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of AZA or Durva | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Related to (R/T) Oral Azacitidine (AZA) | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of Durva | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Oral AZA | 3 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE | 5 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of Durva | 3 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T AZA or Durva | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Discontinuation (D/C) of AZA | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Reduction of Durva | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC Grade (GR) 3 or 4 TEAE | 5 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA or Durva | 1 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T Durva | 2 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 NCI CTC GR 3 or 4 TEAE R/T AZA or Durva | 3 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to D/C of AZA or Durva | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Durva | 1 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 TEAE Leading to Death R/T Oral AZA | 0 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥1 TEAE Leading to Interruption of AZA or Durva | 4 Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | ≥ 1 Serious TEAE R/T Oral AZA | 1 Participants |
Secondary
Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML)
For all participants who received at least one dose of study drug, continuous monitoring for progression to AML occurred in the post treatment follow up period.
Time frame: From first dose and until death, loss to follow-up, withdrawal of consent for further data collection (Up to 91 months)
Population: The ITT population included all enrolled participants who received at least one dose of IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stable Disease (SD) Cohort: Oral Azacitidine | Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML) | 31.3 Percentage of Participants |
| Progressive Disease (PD) Cohort: Oral Azacitidine | Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML) | 18.2 Percentage of Participants |
| Stable Disease Cohort: Oral Azacitidine and Durvalumab | Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML) | 33.3 Percentage of Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML) | 60.0 Percentage of Participants |
Secondary
Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease
A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment.
Time frame: Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Population: Includes participants who had progressive disease at baseline who achieved stable disease.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Progressive Disease (PD) Cohort: Oral Azacitidine | Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease | 36.4 Percentage of Participants |
| Progressive Disease Cohort: Oral Azacitidine and Durvalumab | Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease | 20.0 Percentage of Participants |
Secondary
Serum Plasma Concentration of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Terminal Half-life ( ½) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Time to Maximum Concentration (Tmax) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population
Secondary
Volume of Distribution (Vz/F) of Azacitidine and Durvalumab
Data was not collected
Time frame: Day 1, 8, 15 and 22
Population: Pharmacokinetic population